As of June 1, 2021, Grace will now operate the fine chemical manufacturing services (FCMS) business previously run by Albemarle. For several decades, the FCMS's unyielding focus on innovation and advanced technical expertise have exceeded customer expectations at every phase of the drug/product development process. FCMS extends Grace’s growing pharma portfolio, which includes chromatographic resins, formulation excipients and drug delivery, and pharmaceutical intermediates and APIs.
Grace’s FCMS is a reliable U.S. domestic supplier of RSMs, intermediates and high-value APIs. For more than 40 years, long-tenured teams have supported customers across the full breadth of their small molecule drug substance programs, successfully scaling up many compounds from our integrated US facilities.
From process development through the scale-up of RSMs to complex APIs, we work closely with you to understand your development goals and are with you every step of the way to help you achieve them using the most efficient methods.
In addition to the resources we dedicate to supporting your next breakthrough product, Grace FCMS maintains an active, ongoing program to develop new APIs for several therapeutic indications.
View our portfolio of cGMP active generics and discover how we can support you in optimizing our APIs for use in a wide range of dosage forms.Learn more
The exemplary audit history and regulatory track record translates to a clear and efficient regulatory pathway for you and your product.Learn more
Connect with us to find out more about how an integrated domestic US drug substance partner can help you.